[1]赵婧莎 周紫微 刘婧 刘剑萍 崔鹏.血浆中性粒细胞明胶酶相关脂质运载蛋白与原发性高血压及高血压左心室肥厚的相关性研究[J].心血管病学进展,2022,(5):469-474.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.020]
　ZHAO Jingsha,ZHOU Ziwen,LIU Jing,et al.Association of Elevated Neutrophil Gelatinase-Associated Lipocalin with Essential Hypertension and Hypertensive Left Ventricular Hypertrophy[J].Advances in Cardiovascular Diseases,2022,(5):469-474.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.020]
点击复制

血浆中性粒细胞明胶酶相关脂质运载蛋白与原发性高血压及高血压左心室肥厚的相关性研究()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年5期
页码:
469-474
栏目:
出版日期:
2022-05-25

文章信息/Info

Title:
Association of Elevated Neutrophil Gelatinase-Associated Lipocalin with Essential Hypertension and Hypertensive Left Ventricular Hypertrophy
作者:
赵婧莎1 周紫微1 刘婧1 刘剑萍1 崔鹏2
(1.西南交通大学附属医院 成都市第三人民医院重症医学科,四川 成都 610031;2.西南交通大学附属医院 成都市第三人民医院介入科,四川 成都 610031)
Author(s):
ZHAO Jingsha1; ZHOU Ziwen1; LIU Jing1; LIU Jianping1; CUI Peng2
(1.Department of Intensive Care Unit,The Affiliated Hospital of Southwest Jiaotong University,The Third People’s Hospital of Chengdu,Chengdu 610031,Sichuan,China; 2.Department of Intervention,The Affiliated Hospital of Southwest Jiaotong University,The Third People’s Hospital of Chengdu,Chengdu 610031,Sichuan,China)
关键词:
中性粒细胞明胶酶相关脂质运载蛋白; 高血压; 高血压左心室肥厚; 左心室质量指数
Keywords:
Neutrophil gelatinase-associated lipocalin; Hypertension; Hypertensive left ventricular hypertrophy; Left ventricular mass index
DOI:
10.16806/j.cnki.issn.1004-3934.2022.05.020
摘要:
目的 中性粒细胞明胶酶相关脂质运载蛋白（NGAL）是一种促炎脂肪因子，已被证实与多种心血管疾病相关。而NGAL与高血压及高血压左心室肥厚的关系尚不明确，现探讨血浆NGAL与高血压及高血压左心室肥厚的相关性。方法 纳入2017—2019年在成都市第三人民医院心血管内科住院诊治的高血压患者以及非高血压患者，研究对象共308例，高血压患者187例，非高血压患者（对照组）121例。采用逻辑回归模型分析血浆NGAL与高血压及高血压左心室肥厚的相关性。采用左心室质量指数评估患者是否存在高血压左心室肥厚。结果 与对照组相比，高血压组患者的血浆NGAL水平明显升高[（14.97±2.94）ng/mL vs （12.33±2.88）ng/mL，P＜0.001]。将NGAL作为连续变量分析，在单因素逻辑回归模型中，血浆NGAL与高血压风险增加相关（OR＝1.35，95% CI 1.24～1.48， P＜0.001）。多因素分析显示，血浆NGAL是高血压的独立危险因素（Model2:OR＝1.35，95% CI 1.23～1.48， P＜0.001；Model3:OR＝1.36，95% CI 1.24～1.50， P＜0.001）。与高血压无左心室肥大组相比，高血压左心室肥厚组患者的血浆NGAL水平明显升高[（16.94±2.13）ng/mL vs （13.68±2.67）ng/mL，P＜0.001]。单因素分析显示血浆NGAL升高与高血压患者左心室肥大显著相关（OR＝1.65,95% CI 1.42～1.91, P＜0.001）。多因素分析仍然显示血浆NGAL是高血压左心室肥厚的独立危险因素（Model2：OR＝1.67，95% CI 1.43～1.94， P＜0.001；Model3：OR＝1.69，95% CI 1.43～2.00， P＜0.001）。受试者操作特征曲线分析显示，血浆NGAL对高血压左心室肥厚的预测具有很好的准确性，受试者操作特征曲线下面积为0.83（95% CI 0.77～0.88， P＜0.001）。结论 血浆NGAL水平升高与高血压及高血压左心室肥厚具有相关性。
Abstract:
Objective Neutrophil gelatinase-associated lipocalin(NGAL) is a pro-inflammatory fat factor,which has been proved to be associated with various cardiovascular diseases. The association between NGAL and hypertension and hypertensive left ventricular hypertrophy(LVH) has not been evaluated. This study explored the association between NGAL and hypertension and the influence of NGAL on the LVH. Methods A total of 308 participants(including 187 hypertension patients and 121 non -hypertension patients as control group ) were enrolled in Department of Cardiology,The Third People’s Hospital of Chengdu from 2017 to 2019. Logistic regression model was used to analyze the correlation between plasma NGAL and hypertension and hypertensive LVH. Left ventricular mass index was used to evaluate the presence of hypertensive LVH. Results Compared with the control group,the plasma NGAL level in hypertension group was significantly higher[(14.97±2.94)ng/mL vs (12.33±2.88)ng/mL，P＜0.001]. Using NGAL as a continuous variable,plasma NGAL was associated with an increased risk of hypertension in a univariate logistic regression model(OR＝1.35，95% CI 1.24～1.48， P＜0.001). Multivariate analysis showed that plasma NGAL was an independent risk factor for hypertension(Model2:OR＝1.35，95% CI 1.23～1.48， P＜0.001；Model3:OR＝1.36，95% CI 1.24～1.50， P＜0.001). Compared with the hypertensive group without LVH,the plasma NGAL level in the hypertensive LVH group was significantly higher [(16.94±2.13)ng/mL vs (13.68±2.67)ng/mL，P＜0.001]. Univariate analysis showed that the increase of plasma NGAL was significantly correlated with LVH in patients with hypertension (OR＝1.65,95% CI 1.42～1.91, P＜0.001). Multivariate analysis still showed that plasma NGAL was an independent risk factor for hypertensive LVH(Model2：OR＝1.67，95% CI 1.43～1.94， P＜0.001；Model3：OR＝1.69，95% CI 1.43～2.00， P＜0.001). The receiver operating characteristic curve analysis showed that plasma NGAL had a good accuracy in predicting the LVH in hypertensive subjects,and the area under the operating characteristic curve was 0.83(95% CI 0.77～0.88, P＜0.001). Conclusion Elevated NGAL is associated with hypertension and hypertensive LVH

参考文献/References:

[1] Bakris G,Ali W,Parati G. ACC/AHA versus ESC/ESH on hypertension?guidelines:JACC guideline comparison[J]. J Am Coll Cardiol,2019,73(23):3018-3026.

[2] Dzau VJ,Balatbat CA. Future of hypertension [J]. Hypertension,2019,74(3):450-457.

[3] Kearney PM,Whelton M,Reynolds K,et al. Global burden of hypertension:analysis of worldwide data[J]. Lancet,2005,365(9455):217-223.

[4] Mancia G. Introduction to a compendium on hypertension [J]. Circ Res,2015,116(6):923-924.

[5] Sesso HD,Jiménez MC,Wang L,et al. Plasma inflammatory markers and the risk of developing hypertension in men[J]. J Am Heart Assoc,2015,4(9):e001802.

[6] Hemdahl AL,Gabrielsen A,Zhu C,et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction [J]. Arterioscler Thromb Vasc Biol,2006,26(1):136-142.

[7] Yndestad A,Landr? L,Ueland T,et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure [J]. Eur Heart J,2009,30(10):1229-1236.

[8] Martínez-Martínez E,Buonafine M,Boukhalfa I,et al. Aldosterone target NGAL( neutrophil gelatinase-associated lipocalin) is involved in cardiac remodeling after myocardial infarction through NFκB pathway[J]. Hypertension,2017,70(6):1148-1156.

[9] Whelton PK,Carey RM,Aronow WS,et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention,detection,evaluation,and management of high blood pressure in adults:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines [J]. J Am Coll Cardiol,2018,71(19):e127-e248.

[10] Devereux RB,Alonso DR,Lutas EM,et al. Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy findings [J]. Am J Cardiol,1986,57(6):450-458.

[11] Lang RM,Bierig M,Devereux RB,et al. Recommendations for chamber quantification:a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group,developed in conjunction with the European Association of Echocardiography,a branch of the European Society of Cardiology [J]. J Am Soc Echocardiogr,2005,18(12):1440-1463.

[12] Tarjus A,Martínez-Martínez E,Amador C,et al. Neutrophil gelatinase-associated lipocalin,a novel mineralocorticoid biotarget,mediates vascular profibrotic effects of mineralocorticoids [J]. Hypertension,2015,66(1):158-166.

[13] Eirin A,Gloviczki ML,Tang H,et al. Chronic renovascular hypertension is associated with elevated levels of neutrophil gelatinase-associated lipocalin [J]. Nephrol Dial Transplant,2012,27(11):4153-4161.

[14] Aksan G,?nci S,Nar G,et al. Serum neutroph?l gelat?nase-assoc?ated l?pocal?n levels in patients with non-dipper hypertension [J]. Clin Invest Med,2015,38(2):E53-E62.

[15] Park CG,Choi KM. Lipocalin-2,A-FABP and inflammatory markers in relation to flow-mediated vasodilatation in patients with essential hypertension[J]. Clin Exp Hypertens,2014,36(7):478-483.

相似文献/References:

[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
　SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(5):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
　FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(5):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
　CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(5):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
　ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(5):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
　ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(5):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
　HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(5):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
　ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(5):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]谷阳 史亚非 张刚 张东营 张清.急性ST段抬高型心肌梗死患者血浆中性粒细胞明胶酶相关脂质运载蛋白水平与梗死后心室重构的相关性研究[J].心血管病学进展,2019,(5):836.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.042]
　GU Yang,SHI Yafei,ZHANG Gang,et al.Neutrophil Gelatinase-associated Lipocalin is Associated with Cardiac Remodeling in Patients with ST-segment Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(5):836.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.042]
[10]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
　LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(5):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]

更新日期/Last Update: 2022-06-30